Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People (and their families) who fully understand the study and are willing to sign a consent form
- People who have been diagnosed with type 1 or type 2 diabetes
- People whose HbA1c blood sugar level was below 10% within the last 3 months
- People whose eye is clear enough to allow good quality eye scan (OCT and OCTA) images to be taken
- People who have diabetic macular edema (swelling in the central part of the retina caused by diabetes) that has never been treated before
- People whose eye scan shows a central retinal thickness greater than 300 micrometres, with fluid in or under the retina
- People whose vision in the affected eye falls within a specific range on a standard eye chart test (between 24 and 73 ETDRS letters) on the day they are assigned to a treatment group
- People who are starting treatment within 12 months of their diabetic macular edema diagnosis
- People for whom eye surgery (vitrectomy) and a specific eye injection (conbercept) are both considered safe options by their treating doctor
Who may not be able to join:
- People who have already received any treatment for diabetic macular edema, such as anti-VEGF injections, steroid injections into the eye, or laser treatment to the retina
- People whose macular swelling is caused by a condition other than diabetes, such as age-related macular degeneration, a blocked retinal vein, or eye inflammation
- People who have had any previous surgery inside the eye (note: cataract surgery performed at least 3 months before joining the study may not automatically exclude someone — confirm with trial site)
- People whose vision loss is mainly caused by another eye condition, such as cataracts, advanced diabetic eye disease, glaucoma, or severe short-sightedness
- People who would not be able to attend follow-up appointments for at least 12 months
- People with severe problems affecting the heart, liver, kidneys, lungs, or other major organs
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13612130943
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Best corrected visual acuity change (BCVA); Central subfield thickness (CST) change
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.